McKesson (MCK) Q4 2026 earnings review
Earnings Surge and Massive Buybacks Mask Top-Line Deceleration
McKesson delivered a robust bottom line with Q4 Adjusted EPS up 16% to $11.69, fueled by massive share repurchases ($2.7B in Q4) and margin expansion in Oncology and North American Pharmaceuticals. However, consolidated revenue growth is decelerating, slowing to 6% YoY in Q4 from 23% in Q1, dragged down by softer branded pharma volumes. The Medical-Surgical segment remains a laggard, with operating profit dropping 5% as McKesson prepares for its spin-off, partially selling a 13% stake to Apollo Global. FY27 guidance targets 12-14% EPS growth, projecting a stable but slightly slower growth trajectory than FY26.
🐂 Bull Case
The high-margin Oncology & Multispecialty segment is accelerating, with operating profit up 53% YoY driven by provider solutions and acquisitions like PRISM Vision.
The Board authorized an additional $5.0B for share repurchases, executing $2.7B in Q4 alone, aggressively reducing share count and creating a strong tailwind for FY27 EPS.
🐻 Bear Case
Revenue growth dropped sharply to 3% YoY in Q4 from 25% in Q1, reflecting lower branded pharmaceutical contributions.
Segment adjusted operating profit fell 5% YoY in Q4, a reversing trend highlighting weakness in ambulatory care channels.
⚖️ Verdict: ⚪
Neutral/Bullish. The bottom-line execution is flawless, supported by aggressive share repurchases and high-margin Oncology growth. However, top-line deceleration in the core NA Pharma segment and reversing profits in Medical-Surgical warrant caution.
Key Themes
Oncology & Multispecialty is the Profit Engine
This segment is accelerating, with Q4 Adjusted Operating Profit surging 53% YoY to $385M. Revenue grew 35%. Growth is driven by specialty distribution and the successful integration of acquisitions like PRISM Vision and Core Ventures (Florida Cancer Specialists). The addition of Cancer Care Northwest in April further solidifies the U.S. Oncology Network's footprint, making this segment McKesson's crown jewel.
Top-Line Deceleration in NA Pharma Contradicts Volume Narrative
A concerning trend is emerging in the core North American Pharmaceutical segment. Revenue growth is decelerating sharply, from 25% YoY in Q1 to just 3% in Q4. Management continues to cite 'increased prescription transaction volumes,' but this is contradicted by the stagnating revenue, caused by lower contributions from branded pharmaceuticals. While adjusted operating profit still grew 11% due to a favorable specialty product mix, the topline stagnation is a red flag.
Medical-Surgical Laggard Prepares for Exit
The Medical-Surgical segment continues to struggle, with Q4 adjusted operating profit reversing to a 5% YoY decline ($271M) despite flat revenue (+1%). Lower contributions from the ambulatory care channel are squeezing margins. McKesson is actively preparing for the separation, securing $2.0B in pre-spin financing and agreeing to sell a 13% minority stake to Apollo Global.
Prescription Technology Solutions (RxTS) & AI
RxTS remains a stable, high-margin growth driver. Q4 revenue grew 12% and adjusted operating profit grew 13% to $322M. The segment benefits from higher demand for access and affordability solutions, particularly for complex drugs like GLP-1s. Management's specific investments in technology, including an AI chat tool that resolves 75% of DSCSA inquiries on first contact and automated prior authorizations, are driving measurable operating leverage.
Aggressive Share Repurchases Boosting EPS
Capital allocation is a massive EPS driver. In Q4 alone, McKesson executed $2.7B in share repurchases, heavily weighted by a $2.25B accelerated program. The Board approved an additional $5.0B authorization, bringing the total to $7.7B. This aggressive reduction in share count provides a significant structural tailwind for FY27 EPS.
Macro and Regulatory Pressures on Branded Pharma
While management has previously downplayed the risks of the Inflation Reduction Act (IRA) and Most Favored Nation (MFN) drug pricing models, the Q4 drop in branded pharmaceutical contributions highlights vulnerability to manufacturer pricing actions and broader regulatory scrutiny. Ongoing pricing deflation and potential tariffs remain constant macro risks.
Other KPIs
Generated robust $6.2B in operating cash flow, investing $745M in CapEx. This cash generation provides ample liquidity to fund the massive $7.7B buyback authorization while covering the $381M in annual dividends.
Adjusted Gross Profit increased 10% YoY, outpacing the 6% YoY Q4 revenue growth. This reflects a favorable shift towards higher-margin specialty and oncology distribution, enabling operating leverage despite top-line deceleration.
Guidance
Decelerating. Represents 12-14% YoY growth, down from the 18% growth delivered in FY26. However, it exceeds the company's long-term target, heavily supported by the aggressive $7.7B buyback program.
Stable. Reaffirmed target reflects management's confidence in specialty distribution offsetting the current sluggishness in branded pharmaceuticals.
Stable. The highest growth target across segments, leaning on continuous acquisitions and provider network expansion to maintain double-digit momentum.
Key Questions
Branded Pharma Deceleration
What drove the sudden deceleration in branded pharmaceutical contributions in Q4? Is this a structural pricing issue resulting from regulatory changes, or a timing dynamic?
Medical-Surgical Spin-Off Timeline
With Apollo Global taking a 13% stake in the Medical-Surgical segment and $2.0B in financing secured, what is the exact timeline and structural mechanism for the full separation?
EPS Quality vs Buybacks
How much of the FY27 12-14% EPS growth guidance is reliant on the $7.7B share repurchase authorization versus organic operating profit expansion?